Role of Dexmedetomidine as Synergistic Agent
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorLady Reading Hospital, Pakistan
About this trial
The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.
Eligibility criteria
Qualifiers
Patients of either gender aged between 18 and 65 years.
Patients scheduled for surgical procedures of lower limb requiring subarachnoid anesthesia.
American Society of Anesthesiologists (ASA) physical status classification I or II.
Disqualifiers
Patients with contraindications to subarachnoid anesthesia, including severe coagulopathy, infection at the site of injection, or increased intracranial pressure.
Patients with a history of significant cardiac, respiratory, hepatic, or renal disease.
Pregnant or lactating women.
Patients with a history of substance abuse or dependence.
Trial design
Treatments tested in this trial
- Hyperbaric bupivacaine
- hyperbaric bupivacaine and dexmedetomidine
Treatment groups
166 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov